SCHEMBL25212412

SCHEMBL25212412

COC(=O)c1ccc(Sc2ccc(C)nc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 6/20 0.47
HPGD P15428 5/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MAPK1 P28482 3/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ALDH1A1 P00352 6/20 0.46
MAPT P10636 6/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
LMNA P02545 3/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25216660 0.86 ALDH1A1 (0.50) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL25267522 0.83 MAPK1 (0.45) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL25213750 0.83 ALDH1A1 (0.51) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL25216802 0.83 NNMT (0.51) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL6575703 0.83 CA1 (0.61) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL64763 0.81 MAPK1 (0.67) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL30574349 0.81 MAPK1 (0.67) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL25215309 0.81 CA1 (0.47) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL25252757 0.81 ALDH1A1 (0.46) TDP1KDM4EHPGDKMT2AMEN1
SCHEMBL11478173 0.80 ALDH1A1 (0.61) TDP1KDM4EHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 TDP1 997/4885KDM4E 308/4885HPGD 741/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 TDP1 846/4885KDM4E 301/4885HPGD 501/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 TDP1 846/4885KDM4E 301/4885HPGD 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.